OPKO Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by OPKO Health, Inc. on February 10, 2023. The report details a material amendment to a series of 5% Convertible Promissory Notes originally issued in February 2018.
Key Financial Metrics
The filing does not provide current revenue, profit, cash flow, or liquidity metrics. It focuses exclusively on the terms of a specific debt instrument:
- Debt Instrument: 5% Convertible Promissory Notes.
- Aggregate Principal Amount: $55 million.
- Original Maturity: February 27, 2023 (5 years from issuance).
- Amended Maturity: Extended to January 31, 2025.
- Original Conversion Price: $5.00 per share.
- Amended Conversion Price: Reset to $1.66 per share (calculated as the 10-day volume weighted average price preceding the amendment date plus a 25% premium).
Material Changes
The primary material change reported is the amendment of the 2018 Convertible Notes. Key modifications include:
- Maturity Extension: The maturity date was extended by approximately two years from the original due date to January 31, 2025.
- Conversion Price Reset: The conversion price was significantly reduced from $5.00 to $1.66 per share, increasing the number of shares issuable upon conversion.
- Interest Accrual: Interest continues to accrue on the principal and any unpaid interest until paid in full.
Outlook, Risks, and Unusual Items
Unregistered Securities: The issuance of the Notes and any future shares issued upon conversion are not registered under the Securities Act of 1933, relying instead on the exemption provided by Section 4(a)(2). The Company has not agreed to register these shares.
Management Commentary: The filing contains no forward-looking guidance, outlook, or management commentary regarding future financial performance beyond the terms of the note amendment.
Investor Verification Checklist
- Verify the exact calculation of the 10-day volume weighted average price used to determine the $1.66 conversion price.
- Review the full text of the amended Note (to be filed as an exhibit to the Form 10-K for the year ended December 31, 2022) for any covenants or default provisions not summarized here.
- Assess the dilution impact of the lower conversion price ($1.66 vs. $5.00) on existing shareholders if the notes are converted.
- Confirm the Company's current cash position to evaluate its ability to service the 5% interest on the $55 million principal until the new 2025 maturity date.